Mölnlycke Health Care wins Swedish Sustainability Tech award

“Our strong financial position and continued growth allow us to direct our future and continued investments. At the same time, it is clear that our strategy and previous investments have paid off, enabling close relationships with our customers working alongside them to handle the challenges of healthcare today,” says Zlatko Rihter, CEO of Mölnlycke. Highlights from the year: Continued strong growth at 7.4% compared to previous year and annual sales of EUR 2,064 million with improved profitability. The progress in becoming a leader in sustainable healthcare was recognised with a platinum medal from EcoVadis. Focus on transformation through partnerships commenced in 2024 with the acquisition of P.G.F. Industry Solutions, the strategic partnership with Ondine Biomedical Inc and strategic investments in MediWound and Siren. The joint venture Tamer Mölnlycke Care in Saudi Arabia has started production and there are plans for expansion in India and China. Download and read the full report on www.molnlycke.com/corporate/about/reports For more information, please contact:  [Contact card] Sofia Lindqvist

Barcelona, Spain. 27 March 2025. New study reports that switching patients with chronic wounds to the multi-layered, bordered silicone-coated foam dressing, Mepilex® Border Flex, alongside a clinician educational support programme, resulted in a significant reduction in the number of dressing changes being undertaken and a reduction in dressing-related costs.1  The study, sponsored by Mölnlycke Health Care, and conducted across primary care facilities in Seville, Spain was today presented as an e-poster at the 35th Conference of the European Wound Management Association (EWMA) 2025 in Barcelona, Spain by the principal investigator Dr Andres Roldan Valenzuela, Centro de Salud Mairena del Aljarafe – Cuidad Expo, Seville. The primary outcome of the study was a statistically significant reduction in the number of dressing changes undertaken, prior to and after the switch from a bordered foam dressing (baseline) to  Mepilex® Border Flex; results demonstrated the median number of dressing changes reduced during the study period, from three in a seven-day period to just one.1 Other reported outcomes included:1 32% wounds healed by the final visit 50% reduction in wound area in four weeks in 75% of patients Two thirds (68.7%) reduction in wound area from baseline to the final visit Reduced pain at dressing changes (pain severity scores of 3.1 - 3.3 at baseline associated with previously used dressings, compared to scores of 0.5 - 1.1 recorded with Mepilex® Border Flex at the final visit) 44% reduction in weekly dressing cost per patient (5.38€ less after the dressing switch) No dressing related adverse events Almost all (97%) of the clinicians rated the overall performance of Mepilex® Border Flex to be better than the previously used dressings, while 100% of patients rated Mepilex® Border Flex as ‘good’ to ‘very good’ in terms of overall satisfaction, compared to 65% for the previously used dressings. Dr Andres Roldan Valenzuela, principal investigator commented “The results of this study clearly demonstrate how simple changes to a wound care treatment regime can bring about positive outcomes for both patients and healthcare providers. At a time when healthcare systems and staff are under increasing pressure on both cost and time it is encouraging that there are solutions to help drive efficiencies and improve outcomes for all involved.” For more information, please contact:  [Contact card] Sofia Lindqvist About the study design The study involved 37 adult patients, aged between 30 and 90+ years presenting with wounds that had not reduced in size by >40-50% in the previous month and had been managed with foam dressing (other than Mepilex® Border Flex), for a minimum of four weeks (baseline). Category 2 pressure ulcers (24.3%) and venous leg ulcers (18.9%) were the most common wound types. Patients in the study had Mepilex® Border Flex applied to their wounds for ≥4 weeks, in conjunction with standard of care.  

The Tamer Mölnlycke Care joint venture was initiated in 2021 with the agreement to develop a customised surgical procedure tray factory in Saudi Arabia, with first production expected in Q4 2024. The increased investment allows for an expansion in the range of Mölnlycke products manufactured and distributed in the country and to the neighbouring region. Adding drapes and gowns, emollient range and selected wound care products to the offering allows more healthcare professionals and patients in the region to benefit from Mölnlycke products and solutions. Zlatko Rihter, CEO, Mölnlycke Health Care comments “To ensure we meet customer demand, geographical expansion is a strategic priority for Mölnlycke Health Care. Increased investment in our existing long-term partnership with Tamer Group will importantly enable healthcare professionals and patients in Saudi Arabia access to our quality products and solutions helping to improve outcomes, and is a step closer to realising the potential of this rapidly growing healthcare market.” Speaking on behalf of Tamer Group, Chairman Ayman Tamer adds “This investment is key to enabling future growth in the region as outlined in the Saudi Vision 2030 - supporting the regional healthcare ecosystem, including exporting goods to the Middle East and Africa region, whilst developing local skills and expertise.” Mahmoud Wagih, CEO, Tamer Mölnlycke Care comments “I am delighted to lead this business where Mölnlycke and Tamer will build a strong, long-term successful joint venture, bringing superior health care solutions to our region.” The Tamer Mölnlycke Care joint venture is a long-term agreement between two organisations who have been working in partnership over the past decade; and are committed to meeting customer demand in the evolving healthcare landscape of Saudi Arabia and the wider region. For more information, please contact:  Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560  

Gothenburg 12 April 2024: Mölnlycke, a world leading MedTech company specialised in wound care and wound management, announced today it signed an agreement to acquire P.G.F. Industry Solutions GmbH, the Austrian manufacturer of Granudacyn wound cleansing and moisturising solutions. Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of solution and gel products intended for use in the cleansing, irrigation and moisturisation of various wound types. The high quality and composition of Granudacyn ensures good biocompatibility, allowing it to be effectively used on a broad range of tissues in burns, as well as acute and chronic wounds. Mölnlycke currently distributes Granudacyn in over 50 countries around the world. “With an ageing population in combination with increased chronic wounds, such as diabetic foot ulcers or venous leg ulcers, it is our obligation to help ease the burden of wounds on national healthcare regimes” says Zlatko Rihter, CEO of Mölnlycke Health Care. “The acquisition of P.G.F. and its state-of-the-art manufacturing plant, will allow Mölnlycke to aggressively expand our Granudacyn business to improve the lives of even more patients.” “I’m excited for P.G.F. to become part of Mölnlycke and for the team to continue to manufacture products that support Mölnlycke’s Wound Care mission to help free patients from the burden of wounds” says Peter Fritz, P.G.F. founder and CEO, who will continue to lead this team and manufacturing process from P.G.F.’s Austria headquarters. Closure is expected after certain milestones are reached and will be communicated separately. For more information, please contact: Jennifer Doak Global Communications Director Wound Care Email: jennifer.doak@molnlycke.com Phone: +1 678 206 6179 About Mölnlycke® Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About P.G.F. Industry Solutions P.G.F. Industry Solutions was founded in 2005 by Peter Fritz to develop and produce ecologically compatible hypochlorous acid based products to protect the user and their environment. The company is founded on more than 30 years of experience in research, development, production, and worldwide distribution of medical and measurement products. P.G.F. employs approximately 25 employees and is headquartered in Elixhausen, Austria. www.veriforte.com.

The facility is backed by a group of seven leading global and regional banks, well diversified to match Mölnlycke’s geographical footprint. The banks are BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB as mandated lead arrangers. SEB acted as the coordinator, documentation agent and facility agent for the transaction. For more information, please contact:  Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke   Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics.  Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com 

“At Mölnlycke, we believe that education is a cornerstone of progress in healthcare. The 2025 Future Summit exemplifies our commitment to fostering innovation, enhancing clinical practice, and building partnerships that enable healthcare professionals to improve patient outcomes”, says Emma Wright, Chief Medical Officer at Mölnlycke Health Care. “We are thrilled to bring together such a diverse and accomplished group of experts to shape the future of wound care.” Offering a unique platform for collaboration Set to be a highlight of the professional education calendar, the 2025 Future Summit will host over 130 HCPs from vascular, orthopedic, general, and plastic surgery specialties. With the participation of global faculty leaders, the event will provide a unique platform to explore cutting-edge advancements, share best practices, and foster interdisciplinary collaboration in wound care and surgical excellence. The summit will take place on October 6-7, 2025, in the Netherlands and will be presided over by renowned experts Professor Javad Parvizi and Mr. Ibby Younis.  “The Future Summit reflects the power of partnership and education in driving medical advancements,” says Professor Javad Parvizi, co-president of the summit. “By bringing together experts from diverse specialties, this event creates a unique opportunity to exchange knowledge and redefine standards in wound care and surgery.” A catalyst for innovation Attendees of the summit will be provided with the opportunity to engage in meaningful dialogue, access the latest clinical insights, and participate in interactive workshops led by global faculty leaders.  “This summit is not just an event; it is a catalyst for innovation. It empowers clinicians from across EMEA to collaborate, learn, and apply transformative approaches that will ultimately improve patient care. Mölnlycke’s unwavering commitment to education is truly commendable,” says Mr. Ibby Younis, co-president of the summit.   For more information, please contact:  Sofia Lindqvist  Media Relations Manager Email: sofia.lindqvist@molnlycke.com   Phone: +46 72 255 35 09 

Gothenburg, Sweden. 26 November 2024. The award ceremony was held on 25 November at the Nobel Prize Museum in Stockholm, Sweden where Susanne Larsson, CFO & EVP IT, Digital Enablement, GBS and Indirect Procurement and Caterina Camerani, VP Sustainability at Mölnlycke, accepted the award on behalf of the company. “Our ambition is to transform our business to become a global leader in sustainable healthcare. This award is proof that we are on the right track. We are dedicated to equipping our customers with innovative and sustainable healthcare solutions – for our customers, our employees, our communities and the planet,” says Caterina Camerani, VP Sustainability at Mölnlycke. Mölnlycke ProcedurePak® trays enhance efficiency¹ and help decarbonise healthcare by reducing waste and greenhouse gas (GHG) emissions². ProcedurePak® offers a sterile tray with all necessary components, reducing setup time in the Operating Room by up to 40%¹, and packaging waste by up to 90%² compared to procedures conducted with single-packed products. In one tray package, hospitals can simplify procurement and help ensure patient safety³. The streamlined workflow decreases manual tasks, alleviating stress and freeing up more time for healthcare professionals to focus on patient care. Digital tools like the Mölnlycke Portal and CO2 calculator together with ProcedurePak® Value Report allow hospitals to quantify reductions in waste and GHG emissions, aligning with both sustainability and operational objectives. The judging panel commented: “In recognition of outstanding contributions to sustainability and innovation, this year’s Swedish award celebrates a project that has significantly enhanced operational efficiency while reducing environmental impact. Their commitment to sustainability is further demonstrated by reducing waste, CO2 emissions and preparation time while ensuring patient safety.” For more information, please contact: [Contact card] Sofia Lindqvist About the Cagemini Nordic Sustainability Tech Award The Capgemini Nordic Sustainability Tech Award celebrates organisations across the Nordic region creating innovative technology solutions for a sustainable future. The urgency of the global climate crisis demands ground-breaking technology and IT service innovations that scale across industries. The Nordic Sustainability Tech Award celebrates the inspirational tech pioneers pushing the boundaries of sustainable IT and their role in limiting the environmental and social impact of climate change. References 1 Greiling. A multinational case study to evaluate and quantify time-saving by using custom procedure trays for operation room efficiency. (poster from 2010). 2 Assessing the carbon and waste benefits of moving to Procedure Packs at Royal Liverpool and Broadgreen University Hospitals, NHS Trust, 2011. 3 Optimisation of perioperative procedural factors to reduce the risk of surgical site infection in patients undergoing surgery: a systematic review Key findings P. Calò , F. Catena, D. Corsaro, L. Costantini, F. Falez, B. Moretti, V. Parrinello, E. Romanini, A. Spinarelli, G. Vaccaro, F. Venneri. Discov Health Systems 2, 6 (2023). https://doi.org/10.1007/s44250-023-00019-9.

Gothenburg, Sweden. 25 November 2024. Guillaume Joucla has been appointed new Chief Financial Officer (CFO) at Mölnlycke Health Care. Guillaume Joucla will take office as CFO and member of Mölnlycke’s Executive Leadership Team, as of 1 January 2025. Guillaume Joucla most recently comes from the role of VP Global Finance & Strategic Projects Operating Room Solutions at Mölnlycke. He has also led global cross-functional transformational programmes and held General Manager positions of local operations. Guillaume Joucla wealth of experience from his extensive career within Mölnlycke has equipped him with deep insights into the company’s operations and strategic direction. “We are thrilled to welcome Guillaume to our executive team,” said Zlatko Rihter, CEO of Mölnlycke. “His leadership and expertise will be instrumental in driving our financial strategy and supporting our growth initiatives going forward.” Guillaume Joucla has a distinguished career; before joining Mölnlycke in 2008 he held senior management roles at ProxiMed Services and BioSteril. He holds a Postgraduate degree in Finance & Management from IAE Aix-Marseille Graduate School of Management, and a Master's degree in applied mathematics from Aix-Marseille University. “I am excited to continue my journey at Mölnlycke Health Care and contribute to our ongoing success,” said Guillaume Joucla. “I look forward to working with the talented team to build on Mölnlycke’s strong foundation and contribute to our future as we revolutionise care for people and planet.”   Guillaume will assume the new position as of 1 January 2025 and will be taking over from Susanne Larsson, who is leaving Mölnlycke to pursue an opportunity outside of the organisation. -Ends-  For more information, please contact:  [Contact card] Sofia Lindqvist

Today, Mölnlycke Health Care, a world leading MedTech company, specialising in wound care and wound management announce a research collaboration with Transdiagen (TDG), a precision medicine company developing drugs and diagnostics for chronic wound healing and tissue regeneration. The collaboration aims to use TDG’s novel wound gene signatures to further explore Mölnlycke products. Emma Wright, EVP Chief Medical Officer, Mölnlycke commented, “We are excited by our research collaboration with TDG allowing us to be at the forefront of advanced understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in the under resourced and under prioritised area of wound care.” James Harding, CEO, Transdiagen added “We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG’s novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds.” The collaboration will be initiated shortly. For more information, please contact: Jennifer Doak contact card About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About Transdiagen Transdiagen (TDG) is a precision medicine company developing drugs and diagnostics for chronic wound healing and tissue regeneration. TDG is driven by the molecular understanding and clinical outcome of chronic wounds and to delivering the right treatment, to the right patient, at the right time. TDG has developed novel Ex Vivo models built on clinically validated mRNA biomarkers linking clinical data and patient outcomes. This is the most advanced disease understanding platform for chronic wounds, and powers the creation of novel diagnostics and drugs. The TDG development models and molecular insights translate laboratory data to clinical outcomes, transforming the development lifecycle of novel interventions directing efficacy, product development, disease, and patient selection. TDG is headquartered in the UK. www.transdiagen.com